P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52
Bibliographic record
Abstract
Introduction Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). This post hoc analysis evaluated efficacy at Week 52 in ELEVATE UC 52 (NCT03945188) among patients who met efficacy endpoints at the end of induction (Week 12). Methods Patients (16–80 years) with modified Mayo Score 4–9, endoscopic subscore (ES) ≥2 and rectal bleeding subscore (RBS) ≥1 were randomised 2:1 to etrasimod 2 mg QD or placebo for 12-weeks’ induction followed by a 40-week maintenance period with treat-through design. The proportions of etrasimod-treated patients that sustained clinical remission, endoscopic improvement, endoscopic improvement-histologic remission (EIHR), symptomatic remission and RBS=0 at Week 52 were evaluated among Week 12 responders for those endpoints. Results Among the 289 etrasimod-treated patients, at Week 12, 28.0% (81/289) achieved clinical remission, 37.4% (108/289) endoscopic improvement, 22.8% (66/289) EIHR, 46.4% (134/289) symptomatic remission and 57.4% (166/289) RBS=0. Among the Week 12 responders, the proportion who sustained response at Week 52 was high and ranged from 63.6% for EIHR to 75.3% for RBS=0 (table 1 Etrasimod-treated patients who sustained Week 12 responses at Week 52). Conclusions Etrasimod-treated patients who achieved Week 12 efficacy endpoints were very likely to maintain clinical, endoscopic and histologic efficacy responses at Week 52.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".